ENTERA BIO LTD · Data as of 2026-09-08
late 2026
Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; oral OXM to enter clinic thereafterSource filing
late 2026
We intend to accelerate development and currently expect to submit an IND application to the FDA in late 2026.Source filing
H1 2027
Following the previously announced expansion of the Company's collaboration with OPKO Health ("OPKO") in February 2026, Entera and OPKO intend to file an Investigational New Drug (IND) application for EB612 in the first half of 2027.Source filing
H2 2028
Entera plans to initiate the registrational Phase 3 study in late 2026, with topline results anticipated in the second half of 2028.Source filing
Oct 9–Oct 12
In August 2026, Entera announced that new Phase 2 analysis of EB613 in postmenopausal women with osteoporosis at high risk of fracture was selected for a plenary poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9–12, 2026 in Boston, Massachusetts.Source filing